Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC36 in Obesity or Overweight
NCT07893093Phase 1Recruiting
- Sponsor
- Ascletis Pharma Inc.
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASC36 in obesity and Overweight (16 cohorts), sponsored by Ascletis Pharma Inc. Primary endpoint: Adverse Events at 20 weeks. Started Sep 2026; status: recruiting.
02
Drugs
ASC36
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07893093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893093.